Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Advisory Panel Backs Johnson & Johnson Diabetes Drug Approval-Reuters


Thursday, 10 Jan 2013 05:37pm EST 

Reuters reported that a panel of advisers to the U.S. Food and Drug Administration recommended the agency approve an experimental new treatment for diabetes developed by Johnson & Johnson. The FDA's Endocrinologic and Metabolic Drug Advisory Committee voted 10-5 on Thursday to recommend the agency approve the drug, canagliflozin, for Type 2 diabetes, saying that it proved effective at lowering blood sugar in patients with diabetes, though some panelists had lingering concerns about its potential to cause cardiovascular problems and recommended longer term follow-up. Canagliflozin, which will be sold under the brand name Invokana, is a member of a new class of diabetes drugs known as sodium-glucose co-transporter-2 (SGLT2) inhibitors which lower blood sugar by blocking reabsorbtion of glucose by the kidney and increasing the excretion of glucose in urine. 

Company Quote

105.06
0.47 +0.45%
26 Dec 2014